Fri, Sep 19, 2014, 12:33 AM EDT - U.S. Markets open in 8 hrs 57 mins


% | $
Quotes you view appear here for quick access.

Biogen Idec Inc. Message Board

  • oexwiz oexwiz May 11, 1998 12:07 PM Flag

    Bexxar vs. IDEC-Y2B8: Iodine-131 vs. Ytt

    In a recent press release from IMMU, another
    biotech involved with monoclonal antibodies, they state
    they are going to try Yttrium-90 instead of
    Iodine-131. They hope to achieve better response rates and

    "Until now, Immunomedics has used antibodies labeled
    with radioactive iodine (I-131). Its latest trials
    will attempt to improve response by substituting
    Yttrium-90 for I-131. This will also allow the patients to
    be treated on an outpatient basis and to return home
    after receiving the therapy."

    Bexxar uses
    Iodine-131 (requires isolation/shielding) and is one reason
    I like IDEC (IDEC-Y2B8) and IMMU (LymphoCide)
    better for "hot" antibodies. The biggest downside to
    Yttrium is that it acts much like calcium and has an
    affinity for bone.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Just re-read your post and see that you said "(yttrium) acts like calcium and has an affinity for bone."

      Maybe I misunderstand what that means. What does it mean?

      • 1 Reply to berblady
      • As i understand it, bones will uptake
        yttrium(-90) just like calcium and may cause longer term bone
        marrow damage beyond what other "hot" anti-CD20
        antibodies do in the normal process of attaching to CD20+
        lymphocytes. (There are some approaches to minimizing this.)
        On the other hand, less yttrium-90 tagged antibody
        is needed to be effective (supposedly).

        appears that the risk/reward is worth it since now at
        least two companies, IDEC and IMMU are using it.

329.99+2.41(+0.74%)Sep 18 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Oracle Corporation
NYSEThu, Sep 18, 2014 4:04 PM EDT
Concur Technologies, Inc.
NasdaqGSThu, Sep 18, 2014 4:00 PM EDT
Rite Aid Corporation
NYSEThu, Sep 18, 2014 4:02 PM EDT